Tumor oxygenation level has been regarded as an attractive target to elevate the efficiency of photodynamic therapy (PDT). Cyanobacterial photosynthesis-mediated reversal of tumor hypoxia could enable an oxygen-boosted PDT, but is limited by scant penetration depth and efficiency of external light. Herein, aiming at the dual purposes of reducing biological toxicity induced by long-term light irradiation and alleviating hypoxia, we here introduce a novel-designed CaAl₂O₄:Eu,Nd blue persistent luminescence material (PLM) as the in vivo light source after pre-excited in vitro. The ingenious construction of blue-emitting PLM with “optical battery” characteristics activates cyanobacterial cells and verteporfin simultaneously, which performs the successive oxygen supply and singlet oxygen generation without the long-term external excitation, resulting in the modulated tumor hypoxic microenvironment and enhanced photodynamic tumor proliferation inhibition efficiency. Both in vitro cellular assessment and in vivo tumor evaluation results affirm the advantages of self-produced oxygen PDT system and evidence the notable antineoplastic outcome. This work develops an irradiation-free photosynthetic bacteria-based PDT platform for the optimization of both oxygen production capacity and light utilization efficiency in cancer treatment, which is expected to promote the clinical progress of microbial-based photonic therapy.

肿瘤氧合水平已被视为提高光动力疗法 (PDT) 效率的有吸引力的目标。蓝藻光合作用介导的肿瘤缺氧逆转可以实现氧气增强的 PDT，但受到外部光穿透深度和效率不足的限制。在此，针对降低长期光照引起的生物毒性和缓解缺氧的双重目的，我们在此介绍一种新型CaAl ₂ O ₄ :Eu,Nd 蓝色持久发光材料（PLM）作为体内光源。体外预激后. 具有“光电池”特性的蓝光PLM的巧妙构建，同时激活蓝藻细胞和维替泊芬，在没有长期外部激发的情况下进行连续供氧和单线态氧产生，从而调节肿瘤缺氧微环境，增强光动力肿瘤增殖抑制效率。二者在体外细胞评估和体内肿瘤评估结果肯定了自产氧PDT系统的优势，并证明了显着的抗肿瘤效果。这项工作开发了一种基于光合细菌的无辐照光动力治疗平台，用于优化癌症治疗中的氧气生产能力和光利用效率，有望推动基于微生物的光子治疗的临床进展。